Gilead
Biktarvy’s Benefits Extend in Older Adults With HIV
Five-year follow-up data from the triple combination HIV therapy showed high rates of disease suppression and ...
FEBRUARY 20, 2025
One-Fourth of Initial PrEP Prescriptions Not Dispensed
Approximately one in four first prescriptions for oral pre-exposure prophylaxis for HIV prevention are not ...
OCTOBER 16, 2024
FDA Approves Biktarvy Label Update With Data for Use During Pregnancy
The FDA approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy for ...
APRIL 29, 2024
Long-Acting Oral Combo for HIV Maintains Viral Suppression at Week 24
The investigational oral combination of islatravir and lenacapavir showed the combination maintained a high rate of ...
APRIL 12, 2024
FDA Expands Indication of Biktarvy for Resistant HIV
The FDA expanded the indication for bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF; Biktarvy, Gilead) to ...
FEBRUARY 29, 2024
Oral Bridging of Lenacapavir Maintains Viral Suppression Among HIV Patients
Oral bridging of lenacapavir enabled patients to maintain viral suppression of their HIV after missed doses of ...
JULY 26, 2023
FDA Expands Indication for Veklury to Treat COVID-19 Patients With Renal Impairment
With this approval, Veklury is now the first and only approved antiviral COVID-19 treatment that can be used across ...
JULY 14, 2023
Man Sentenced to 15 Years for Distributing $230 Million in Fraudulent HIV Drugs
U.S. District Cour Judge Raag Singhal sentenced Lazaro Hernandez to 15 years for his part in the distribution of ...
JUNE 28, 2023
Lenacapavir’s Action May Curb HIV Infection Risk
Lenacapavir (Sunlenca, Gilead) may inhibit virion maturation by blocking the formation of HIV-capsid pentamers, ...
MAY 30, 2023
Faster Viral Suppression With Biktarvy Among Patients With Advanced HIV
Biktarvy is associated with faster CD4 cell count recovery and favorable virologic outcomes compared with other ...
MAY 5, 2023
Remdesivir Reduces Readmission Risk by 16% Among Immunocompromised Patients With COVID-19
Remdesivir (Veklury, Gilead) may reduce risk for hospital readmission by as much as 16% among immunocompromised ...
APRIL 21, 2023
FDA Approves Sunlenca for Adults With Resistant HIV
The FDA approved lenacapavir, a first-in-class, long-acting HIV capsid inhibitor, which is injected twice ...
DECEMBER 22, 2022
